Clinical trial · Observational
Identification of Novel Biomarkers of Response to Systemic Treatments in Renal Cell Cancer
A Retrospective Translational Study to Identify Novel Biomarkers of Response to Systemic Treatments in Renal Cell Cancer
NCT04060537CI-TRIAL-00040125ARTIST_RCCunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study aims to investigate changes inside kidney cancers (also known as Renal Cell Carcinoma or RCC), and in normal kidney surrounding the tumour, when patients are treated with systemic therapy. Samples, radiological images and data from a previous trial (NeoSUN) will be analysed and/or reanalysed, in accordance with the consent of NeoSUN participants.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Renal Cell | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Application of machine learning | Other | — | UNRESOLVED |
| Laboratory analysis of samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Research
- description
- Patients with Renal Cell Carcinoma who have had previous systemic treatment, with adequate tissue samples and radiological data
- interventionNames
- Other: Laboratory analysis of samples
- Other: Application of machine learning
Primary outcomes (5)
- measure
- Biological identification of biomarkers of response to systemic treatment in Renal Cell Cancer.
- timeFrame
- 2 years
- description
- Using data from RNA sequencing of tumour tissues, the outcome is to identify novel biomarkers of response.
- measure
- Radiological identification of biomarkers of response to systemic treatment in Renal Cell Cancer.
- timeFrame
- 2 years
- description
- Using data from MRI imaging by analysis of the tumour microenvironment and machine learning interrogation of output data, the outcome is to identify novel biomarkers of response.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged 18 years or older 2. Diagnosis of renal cell cancer (any stage). 3. Patient received systemic treatment for their renal cancer at Cambridge University Hospitals NHS Foundation Trust. 4. Patients must have consent in place, for the use of tissue and imaging to be used for the purposes of clinical research; * Use of tissue not required for their diagnosis or treatment to be stored and used for the purposes of clinical research, which may include genetic research. * Use of relevant sections of their medical records, or by relevant regulatory authorities, where my tissue is being used for research, giving permission for those individuals to have access to their medical records. 5. Participants must also meet at least one of the following criteria to be eligible: 1. For tissue analysis: Patient must have tumour tissue and/or normal adjacent kidney stored (either as formalinfixed paraffin-embedded tissue, or as 'fresh frozen' tissue). 2. For imaging analysis: Patient must have had at least 1 scan (either CT or MRI) within 28 days of starting treatment with systemic treatment for their cancer. Exclusion Criteria: None
References
Publications (0)
Data not yet available
No reference posted for this study.